Characteristics of AMA-positive patients with or without a liver biopsy
| Features | Liver biopsy (n=48) | No liver biopsy (n=42) | p Value |
| Hispanic/non-Hispanic (%) | 32/16 (66.7) | 28/14 (66.7) | >0.999 |
| Sex: female (%) | 42/6 (87.5) | 23/19 (54.8) | 0.001 |
| Alcohol (%) | 14/34 (29.2) | 18/24 (42.9) | 0.193 |
| Substance abuse (%) | 12/36 (25.0) | 10/32 (23.8) | >0.999 |
| Overweight or obese (%) | 40/8 (83.3) | 32/10 (76.2) | 0.438 |
| DM (%) | 11/36 (23.4) | 10/31 (24.4) | >0.999 |
| Age mean (median, range) | 52 (54, 14–77) | 54 (55, 25–79) | 0.533 |
| Laboratory | |||
| Platelet count 150−450×109/L | 232 (225, 53–619) | 203 (205, 7–417) | 0.449 |
| Albumin, mean (median, range) (g/dL) | 3.6 (3.9, 1.9–4.9) | 3.9 (4.1, 2.5–5.1) | 0.070 |
| ALT, mean (median, range) (IU/L) | 153 (69, 15–1540) | 102 (72, 8–311) | 0.958 |
| AST, mean (median, range) (IU/L) | 144 (81, 19–960) | 100 (64, 12–516) | 0.271 |
| AP, mean (median, range) (IU/LT) Total bilirubin mean (median) (mg/dL) | 316 (199, 72–1357) 2.47 (0.95, 0.2–19.5) | 164 (114, 62–492) 1.52 (0.95, 0.1–20.6) | 0.001 0.283 |
| APRI mean (median, range) | 4.728 (2.292, 0.478–41.611) | 5.399 (1.338, 0.210–121.429) | 0.075 |
| FIB-4 mean (median, range) | 4.138 (2.116, 0.721–25.494) | 7.347 (1.683, 0.497–167.571) | 0.176 |
| ANA (%) | 14/31 (31.1) | 12/25 (32.4) | >0.999 |
| F-actin Y (%) | 19/26 (42.2) | 9/24 (27.3) | 0.234 |
| HCV (%) | 8/40 (16.7) | 9/33 (21.4) | 0.379 |
| HBV (%) | 1/47 (2.1) | 1/41 (2.4) | >0.999 |
| Imaging | |||
| Steatosis (%) | 14/28 (33.3) | 11/24 (31.4) | >0.999 |
| Varices Y/N, (%) | 9/36 (20) | 7/30 (18.9) | >0.999 |
| Ascites (%) | 7/39 (15.2) | 7/35 (16.7) | >0.999 |
| Therapy | |||
| URSO (%) | 22/26 (45.8) | 4/38 (9.5) | <0.001 |
ALT, alanine aminotransferase; ANA, antinuclear antibody; AP, alkaline phosphatase; APRI, AST to Platelet Ratio Index; AST, aspartate aminotransferase; DM, diabetes mellitus; FIB-4, Fibrosis-4; HBV, hepatitis B virus; HCV, hepatitis C virus; URSO, ursodeoxycholic acid.